Piper Sandler analyst Edward Tenthoff assumedcoverage of Biomea Fusion (BMEA) with an Overweight rating and $7 price target The company is developing icovamenib to treat diabetes, a covalent menin inhibitor, the analyst tells investors in a research note. Piper views Biomea as an emerging diabetes and obesity play.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue